


Box seq GP 1645
#9c 5/1/98
PATENT



Serial No.: 08/750,101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Dolly, et al.

Serial No.: 08/750,101

Filed: May 1, 1997

For: Modification of Clostridial
Toxins For Use As Transport
Proteins

Examiner: Nita Minnifield

Group Art Unit: 1645

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail addressed to the Assistant Commissioner For Patents, Washington, D.C. 20231 on:

Date of Deposit: March 31, 1998

STANLEY MALEC
Print Name

Signature: Stanley Malec

Date of Signature: March 31, 1998

STATEMENT PURSUANT TO 37 CFR 1.821(f) AND
AMENDMENT OF SPECIFICATION TO INCORPORATE
SEQUENCE LISTING

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

APR 07 1998

Sir,

MAILING CUSTOMER SERVICE

Applicant affirms that the Computer Readable Copy of the Sequence Listing, submitted herewith, is the same as the paper copy of the Sequence Listing, also submitted herewith. No new matter has been added to the Application as a result of the submission of the Sequence Listing. This statement is submitted as required by 37 CFR 1.821(f).

Additionally, please amend the specification by replacing pages 47 through 51 with the accompanying new pages 47 through 51, which contain a Sequence Listing in accordance with the rules of the United States Patent and Trademark Office. No new matter has been added to the specification as a result of this Amendment.


Docket No.: 17044
Filing Date: May 1, 1997

PATENT

No fee is believed due in connection with this communication. However, if Applicants are in error, the Commissioner is hereby authorized to charge Deposit Account No. 07-0835 the appropriate fees.

Respectfully submitted,

Date: 3/31/98


Carlos A. Fisher
Registration No. 36,510
ALLERGAN, INC.
T2-2E
Legal Department
2525 Dupont Drive
Irvine, CA. 92612
Tel: (714) 246-4920
Fax: (714) 246-4249



RECEIVED

APR 3 1998

LEGAL / PATENTS

Application No.: 8/750101

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s)

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE